Lewy pathology and neurodegeneration in premotor Parkinson's disease

Movement Disorders

Volumn 27, Issue 5, 2012, Pages 597-607

  Del Tredici, Kelly ^a   Braak, Heiko ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

synuclein; Autonomic nervous system; Enteric nervous system; Incidental Lewy body disease; Lewy body disease; Lewy neurites bodies; Neurodegeneration; Neuron to neuron transmission; Parkinson's disease; PARS; Premotor Parkinson's disease; Spinal cord; Sporadic Parkinson's disease; Superior cervical ganglion

Indexed keywords

ALPHA SYNUCLEIN; NEUROMELANIN; TYROSINE 3 MONOOXYGENASE;

ANATOMY; ARTICLE; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; IMMUNOREACTIVITY; LEWY BODY; NERVE DEGENERATION; NEUROPROTECTION; OLFACTORY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SPINAL CORD; SUBSTANTIA NIGRA; SYMPATHETIC GANGLION; TAUOPATHY;

HUMANS; LEWY BODIES; LEWY BODY DISEASE; MOTOR NEURONS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84859834711     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24921     Document Type: Article

References (196)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 284-386.
2. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 388: 839-840.
3. Dickson DW. α-Synuclein and the Lewy body disorders. Curr Opin Neurol 2001; 14: 423-432.
4. Norris EH, Giasson BI, Lee VM. α-Synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 2004; 60: 17-54.
5. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157.
6. Martinez-Vincente, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007; 6: 352-361.
7. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131: 1969-1978.
8. Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009; 118: 329-347.
9. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, Uchichara T. Pale neurites, premature α-Synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol 2012; 22: 67-78.
10. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994; 88: 493-500.
11. Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol 1992; 83: 525-529.
12. Irizarry MC, Growdon W, Gómez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998; 15: 112-116.
13. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241-1253.
14. Braak H, Sandmann-Keil D, Gai W, Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 1999; 265: 67-69.
15. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-210.
16. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67-72.
17. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007; 17: 24-30.
18. Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008; 131: 642-650.
19. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009; 201: 1-119.
20. Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body disease. Ann Neurol 2002; 52: 205-210.
21. den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960; 23: 283-290.
22. Hirsch EC, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 334: 345-347.
23. Porta EA. Pigments in aging: an overview. Ann N Y Acad Sci 2002; 959: 57-65.
24. Sulzer D, Mosharov E, Talloczy Z, Zucca FA, Simon JD, Zecca L. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic reponses during aging and disease. J Neurochem 2008; 106: 24-36.
25. Duda JE, Lee VMY, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res 2000; 61: 121-127.
26. Chung KKK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24: 7-14.
27. Lee HG, Zhu X, Takeda A, Perry G, Smith MA. Emerging evidence for the neuroprotective role of α-synuclein. Exp Neurol 2006; 200: 1-7.
28. Trojanowski JQ, Lee VM. Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in the brain. Parkinsonism Relat Disord 2007; 7: 247-251.
29. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging 2010; 31: 99-103.
30. Halliday GM, McCann H. Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms. Exp Neurol 2008; 209: 12-21.
31. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson's disease. Parkinsonism Rel Disord 2009; 15( Suppl 3): S1-S5.
32. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133: 1755-1762.
33. Halliday GM, Lees AJ, Stern M. Milestones in Parkinson's disease-clinical and pathologic features. Mov Disord 2011; 26: 1015-1021.
34. Saha AR, Hill J, Utton MA, et al. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 2004; 117: 1017-1024.
35. Del Tredici K, Duda JE. Peripheral Lewy pathology in Parkinson's disease and incidental Lewy body disease: four cases. J Neurol Sci 2011; 310: 100-106.
36. Dugger BN, Dickson DW. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol 2010; 120: 633-639.
37. Beach TG, Adler CH, Sue LL, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008; 115: 445-451.
38. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 1987; 84: 5976-5980.
39. Gai WP, Blumbergs PC, Geffen LB, Blessing WW. Age-related loss of dorsal vagal neurons in Parkinson's disease. Neurology 1992; 42: 2106-2111.
40. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-287.
41. Jellinger KA. Morphological substrates of dementia in parkinsonism: a critical update. J Neural Trans Suppl 1997; 51: 57-82.
42. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 1997; 144: 202-213.
43. Henderson JM, Carpenter K, Cartwright H, Halliday GH. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 2000; 123: 1410-1421.
44. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60: 337-341.
45. Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004; 25: 19-23.
46. Orimo S, Uchihara T, Kanazawa T, Itoh Y, Wakabayashi K, Kakita A. Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. Neuropathol Appl Neurobiol 2011; 37: 791-802.
47. Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol 2011; 69: 13-21.
48. Braak H, Bohl JR, Müller CM, Rüb U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21: 2042-2051.
49. Braak H, Del Tredici K, Gai WP, Braak E. Alpha-synuclein is not a requisite component of synaptic boutons in the adult human central nervous system. J Chem Neuroanat 2001; 20: 245-252.
50. Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 1985; 18: 552-555.
51. Braak H, Thal DR, Del Tredici K. Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases. J Neural Transm 2011; 118: 809-819.
52. Forno LS, Sternberger LA, Sternberger NH, Strefling AM, Swanson K, Eng LF. Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett 1986; 64: 253-258.
53. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988; 76: 217-221.
54. Oyanagi K, Wakabayashi K, Ohama E, et al. Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson's disease. Acta Neuropathol 1990; 80: 558-559.
55. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79: 581-583.
56. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991; 14: 153-197.
57. Takeda S, Yamazaki K, Miyakawa T, Arai. Parkinson's disease with involvement of the parasympathetic ganglia. Acta Neuropathol 1993; 86: 397-398.
58. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 38( Suppl 2): 2-7.
59. Wakabayashi K, Takahashi H. The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol 1997; 94: 287-289.
60. Korczyn A. Autonomic nervous system disturbances in Parkinson's disease. Adv Neurol 1990; 53: 463-468.
61. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-596.
62. Goldstein DS, Sharabi Y, Karp BI, et al. Cardiac sympathetic denervation preceding motor signs in Parkinson's disease. Clin Auton Res 2007; 17: 118-121.
63. O'Sullivan SS, Williams DR, Gallagher DW, et al. Non-motor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008; 23: 101-106.
64. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15( Suppl 1): 14-20.
65. Löhle M, Storch A, Reichmann H. Beyond tremor and rigidity: non-motor features of Parkinson's disease. J Neural Transm 2009; 116: 1483-1492.
66. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25: 2493-2500.
67. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 2011; 26: 775-783.
68. Chaudhuri KR. The debate of motor versus non-motor aspects of Parkinson's disease: time for marriage. Basal Ganglia 2011; 1: 47-48.
69. Stern MB, Siderowf AD. Parkinson's at risk syndrome: can Parkinson's disease be predicted? Mov Disord 2010; 25( Suppl 1): S89-S93.
70. Forno LS. Concentric hyalin intraneuronal inclusions of Lewy type in the brain of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969; 17: 557-575.
71. Forno LS, Norville RL. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol 1976; 34: 183-197.
72. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999; 52: 1269-1271.
73. Klos KJ, Ahlskog JE, Josephs KA, et al. Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 2006; 66: 1100-1102.
74. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21: 2062-2067.
75. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007; 22: 1581-1586.
76. Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 2007; 66: 354-362.
77. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 2007; 68: 2012-2018.
78. Fujishiro H, Frigerio R, Burrnett M. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008; 23: 1085-1092.
79. Ikemura M, Saito Y, Sengoku Y, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008; 67: 945-953.
80. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006; 12: 284-295.
81. Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related α-synucleinopathy in aging. J Neuropathol Exp Neurol 2004; 63: 742-749.
82. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
83. Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-426.
84. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical parkinson disease. Arch Neurol 2008; 65: 1074-1080.
85. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is presymptomatic Parkinson's disease. Acta Neuropathol 2008; 115: 437-444.
86. Frigerio R, Fujishiro H, Maraganore DM, et al. Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Arch Neurol 2009; 66: 1114-1119.
87. Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009; 68: 816-822.
88. Stephenson R, Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features and detection strategies. Mov Disord 2009; 24( Suppl 2): S665-S670.
89. Adler CH, Connor DJ, Hentz JG. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 2010; 25: 642-646.
90. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phophorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689-702.
91. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010; 119: 703-713.
92. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally-followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-415.
93. Goetz CG, Power W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-1028.
94. Beach TG, White CK, 3rd, Hladik CL, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 2009; 117: 169-174.
95. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010; 25( Suppl 1): S78-S82.
96. Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord 2010; 25: 2508-2515.
97. Korczyn A, Gurevich T. Parkinson's disease: before the motor symptoms and beyond. J Neurol Sci 2010; 289: 2-6.
98. Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K. Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 2004; 54: 682-687.
99. Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol 2009; 118: 777-784.
100. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005; 109: 583-588.
101. Miki Y, Mori F, Wakabayashi K, Kuroda N, Orimo S. Incidental Lewy body disease restricted to the heart and stellate ganglion. Mov Disord 2009; 24: 2299-2301.
102. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? Q J Med 1999; 92: 473-480.
103. Hawkes CH. Olfaction in neurodegenerative disorder. Mov Disord 2003; 18: 364-372.
104. Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat 2007; 211: 117-124.
105. Sengoku R, Saito Y, Ikemura M, et al. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 2008; 67: 1072-1083.
106. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment, and motor dysfunction. Acta Neuropathol 2009; 117: 613-634.
107. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599-614.
108. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-536.
109. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role of system degenerations, including Alzheimer's disease. Neuroscience 1989; 23: 389-398.
110. Morrison LA, Sidman RL, Fields BN. Direct spread of reovirus from the intestinal lumen to the central nervous system through vagal autonomic nerve fibers. Proc Natl Acad Sci U S A 1991; 88: 3852-3856.
111. McBride PA, Schulz-Schaeffer WJ, Donaldson M, et al. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol 2001; 75: 9320-9327.
112. Phillips RJ, Walter GC, Wilder SL, Baronowski EA, Powley TL. Alpha-synuclein immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 2008; 153: 733-750.
113. Jang H, Boltz D, Sturm-Ramirez K, et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A 2009; 106: 14063-14068.
114. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317-325.
115. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010; 5: e8762.
116. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ. The expression of alpha, beta-, and gamma-synucleins in olfactory mucosa. Exp Neurol 1999; 160: 515-522.
117. Witt M, Borman K, Gudziol V, et al. Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov Disord 2009; 15: 93-105.
118. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002; 125: 2431-2445.
119. Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 2008; 63: 7-15.
120. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendsde HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-181.
121. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with the risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-173.
122. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128: 126-137.
123. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir. Potential early markers of Parkinson's disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-851.
124. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its role in the regulation of arousal and autonomic function. Part I: principles of functional organisation. Curr Neuropharmacol 2008; 6: 235-253.
125. Benarroch EE. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009; 73: 1699-1704.
126. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev 2003; 42: 33-84.
127. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009; 10: 211-223.
128. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130-1133.
129. Gonera EG, Van't Hof M, Berger HJC, Van Weel C, Horstink NWIM. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997; 12: 871-876.
130. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: control study. Mov Disord 2000; 15: 669-677.
131. Leentjens A, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003; 18: 414-418.
132. Lehmke MR. Depression in Parkinson's disease. Eur J Neurol 2008; 15( Suppl 1): 21-25.
133. Braak H, Sastre M, Bohl JRE, de Vos RAI, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113: 421-429.
134. Craig AD. Pain mechanisms: labeled lines versus convergence in central processing. Ann Rev Neurosci 2003; 26: 1-30.
135. Tracey I. Nociceptive processing in the human brain. Curr Opin Neurobiol 2005; 15: 478-487.
136. Ford B. Parkinson's disease: pain in Parkinson's disease: the hidden epidemic. Nat Rev Neurol 2009; 2: 242-243.
137. Ford B. Pain in Parkinson's disease. Mov Disord 2010; 25( Suppl 1): S98-S103.
138. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Prac Neurol 2006; 2: 95-106.
139. Scherder E, Wolters E, Polman C, Serfeant J, Swaab D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev 2005; 29: 1047-1056.
140. Koller WC. Sensory symptoms in Parkinson's disease. Neurology 1984; 34: 957-959.
141. Defazio G, Beradelli A, Fabrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008; 65: 1191-1194.
142. Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry 2009; 17: 269-275.
143. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 2006; 123: 231-243.
144. 123]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand 1998; 97: 307-314.
145. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO, 3rd. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000; 133: 338-347.
146. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scinitgraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18: 890-897.
147. Matsui H, Nishinaka K, Oda N, Kamatsu K, Kubori T, Udaka H. Does cardiac metiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006; 12: 284-288.
148. Postuma RB, Gagnon JF, Vendette M, Montplaisir. Idiopathic REM sleep behavior disorder in the transition to degenerative disease. Mov Disord 2009; 24: 2225-2232.
149. Postuma RB, Lanfranchi PA, Blais H, Gagnon JF, Montplaisir. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord 2010; 14: 2304-2310.
150. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 2010; 25: 2296-2303.
151. Schenk CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996; 46: 383-393.
152. Lagi A, Spini S. Clinostatic hypertension and orthostatic hypotension. Clin Cardiol 2010; 33: E10-E15.
153. Sommers S, Aral-Becher B, Jost W. Nondipping in Parkinson's disease. Parkinsons Dis 2011; 2011: 897586.
154. Schmidt C, Berg D, Herting B, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 2009; 24: 2136-2142.
155. Bateson MC, Gibberd FB, Wilson RSE. Salivary symptoms in Parkinson's disease. Arch Neurol 1973; 29: 274-275.
156. Edwards LL, Quigley EM, Harned RK, Hofmann R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994; 1: 15-25.
157. Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson's disease. Clin Neuropharmacol 1999; 22: 213-215.
158. Tumilasci OR, Cersósimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord 2006; 21: 660-667.
159. Cersósimo MG, Tumilasci OR, Raina GB, et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci 2009; 150: 150-151.
160. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's. Gastroenterology 1984; 87: 848-856.
161. Shannon KM, Deshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2011 Jul 15. doi: 10.1002/mds.23838.
162. Pouclet H, Lebouvier T, Coron E, et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol Dis 2012; 45: 305-309.
163. Costa M, Brookes SJH, Henning GW. Anatomy and physiology of the enteric nervous system. Gut 2000; 47: 15-19.
164. Travagli RA, Hermann GE, Browning KN, Rogers RC. Brainstem circuits regulating gastric function. Ann Rev Physiol 2006; 68: 279-305.
165. Benarroch EE. Enteric nervous system: functional organization and neurologic implications. Neurology 2007; 69: 1953-1957.
166. Cersósimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008; 23: 1065-1075.
167. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009; 36: 96-102.
168. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995; 346: 861-864.
169. Anlauf M, Schäfer MK, Eiden L, Weihe E. Chemical coding of the human gastrointestinal nervous system. Cholingergic, VIPergic, and catecholaminergic phenotypes. J Comp Neruol 2003; 459: 90-111.
170. Abbott RD, Ross GW, White LR, et al. Environmental, life-style, and physical precursors of the clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 2003; 250( Suppl 3): III30-III39.
171. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2: 107-116.
172. Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation-critique and recommendations by Movement Disorders Task Force on Rating Scales for Parkinson's disease. Mov Disord 2009; 24: 635-646.
173. Savica R, Cartin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009; 73: 1752-1758.
174. Jost WH. Gastrointestinal dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 69-73.
175. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol 1988; 7: 299-305.
176. Braak H, Müller CM, Rüb U, Ackermann H, et al. Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm Suppl 2006; 70: 89-97.
177. Lopez OL, Becker JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002; 59: 43-46.
178. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer's disease. J Neuropathol Exp Neurol 2003; 62: 363-367.
179. Geddes JW. α-Synuclein: a potent inducer of tau pathology. Exp Neurol 2005; 58: 186-190.
180. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 2006; 65: 685-697.
181. Halliday GM, Holton JL, Revesz R, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122: 187-204.
182. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of α-synuclein and its aggregates. J Neurosci 2005; 25: 6016-6024.
183. Desplats P, Lee H-L, Bae E-J, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13004-13005.
184. Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010; 285: 9262-9272.
185. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010; 6: 702-706.
186. Hansen C, Angot E, Bergström AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725.
187. Dunning CJ, Revews JF, Steiner JA, Brundin P. Can Parkinson's disease pathology be propagated from one neuron to another? Prog Neurobiol 2011 Nov 18. doi no.: 10.1016/j.pneurobio.2011.11.003.
188. Mikolaenko I, Pletnikova O, Kawas CH, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 2005; 64: 156-162.
189. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Rel Disord 2002; 8: 277-284.
190. Wolters EC, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm 2006; 70( Suppl): 309-319.
191. Chaudhuri KR, Healy DG, Shapira AH. Non-motor symptoms of Parkinson's disease. Lancet Neurol 2006; 5: 235-245.
192. Martinez-Martin P, Schapira AHV, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22: 1623-1629.
193. Gaig C, Tolosa E. When does Parkinson begin? Mov Disord 2009; 24( Suppl 2): S656-S664.
194. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Patterns of motor and non-motor features in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 846-850.
195. Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011; 32: 857-863.
196. van Rooden SM, Colas M, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011; 26: 51-58.